Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch P… Read more
Market Cap & Net Worth: Beta Bionics, Inc. Common Stock (BBNX)
Beta Bionics, Inc. Common Stock (NASDAQ:BBNX) has a market capitalization of $468.42 Million ($468.42 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12529 globally and #5368 in its home market, demonstrating a -2.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beta Bionics, Inc. Common Stock's stock price $10.64 by its total outstanding shares 44024631 (44.02 Million).
Beta Bionics, Inc. Common Stock Market Cap History: 2025 to 2026
Beta Bionics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $1.34 Billion to $468.42 Million (0.00% CAGR).
Index Memberships
Beta Bionics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #338 of 976 |
Weight: Beta Bionics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Beta Bionics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beta Bionics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.38x
Beta Bionics, Inc. Common Stock's market cap is 13.38 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.34 Billion | $100.25 Million | -$73.20 Million | 13.38x | N/A |
Competitor Companies of BBNX by Market Capitalization
Companies near Beta Bionics, Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to Beta Bionics, Inc. Common Stock by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Beta Bionics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Beta Bionics, Inc. Common Stock's market cap moved from $1.34 Billion to $ 468.42 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $468.42 Million | -65.08% |
| 2025 | $1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Beta Bionics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $468.42 Million USD |
| MoneyControl | $468.42 Million USD |
| MarketWatch | $468.42 Million USD |
| marketcap.company | $468.42 Million USD |
| Reuters | $468.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.